CoChat

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

Open access
Memon, Danish, Schoenfeld, Adam J., Ye, Darwin, Fromm, George, Rizvi, Hira, Zhang, Xiang, Keddar, Mohamed Reda, Mathew, Divij, Yoo, Kyung Jin, Qiu, Jingya, Lihm, Jayon, Miriyala, Jayalaksmi, Sauter, Jennifer L., Luo, Jia, Chow, Andrew, Bhanot, Umesh K., McCarthy, Caroline, Vanderbilt, Chad M., Liu, Cailian, Abu-Akeel, Mohsen, Plodkowski, Andrew J., McGranahan, Nicholas, Łuksza, Marta, Greenbaum, Benjamin D., Merghoub, Taha, Achour, Ikbel, Barrett, J. Carl, Stewart, Ross, Beltrao, Pedro, Schreiber, Taylor H., Minn, Andy J., Miller, Martin L., Hellmann, Matthew D. · 2024 · Cancer Cell
Cited by 207

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFNγ response genes. Upregulation of IFNγ response genes is associated with putative routes of resistance characterized by signatures of persistent IFN signaling, immune dysfunction, and mutations in antigen presentation genes which can be recapitulated in multiple murine models of acquired resistance to PD-(L)1 blockade after in vitro IFNγ treatment. Acquired resistance to PD-(L)1 blockade in NSCLC is associated with an ongoing, but altered IFN response. The persistently inflamed, rather than excluded or deserted, tumor microenvironment of acquired resistance may inform therapeutic strategies to effectively reprogram and reverse acquired resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2023.12.013

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 207

Metadata

Authors
Memon, D., Schoenfeld, A. J., Ye, D., Fromm, G., Rizvi, H., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., Lihm, J., Miriyala, J., Sauter, J. L., Luo, J., Chow, A., Bhanot, U. K., McCarthy, C., Vanderbilt, C. M., Liu, C., Abu-Akeel, M., Plodkowski, A. J., McGranahan, N., Łuksza, M., Greenbaum, B. D., Merghoub, T., Achour, I., Barrett, J. C., Stewart, R., Beltrao, P., Schreiber, T. H., Minn, A. J., Miller, M. L., & Hellmann, M. D.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2024-02
Volume
42
Issue
2
Pages
209-224.e9
ISSN
1535-6108 (ISSN-L)
OpenAlex
W4390739342
Cited by
207
References
40
FWCI
31.61
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. https://app.cochat.ai/papers/10.1016/j.ccell.2023.12.013
The paper
Memon, D., Schoenfeld, A. J., Ye, D., Fromm, G., Rizvi, H., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., Lihm, J., Miriyala, J., Sauter, J. L., Luo, J., Chow, A., Bhanot, U. K., McCarthy, C., Vanderbilt, C. M., Liu, C., . . . Hellmann, M. D. (2024). Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. https://doi.org/10.1016/j.ccell.2023.12.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.